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Survival in patients with multiple myeloma (MM) hassignificantly improved during the last decades due to theintroduction of novel therapies. In transplant-eligiblepatients with newly diagnosed multiple myeloma
(NDMM) the depth of response following induction therapy is
associated with a better progression free survival (PFS) and
overall survival (OS).1,2 However, it is currently unknown
whether further improvement in response by increasing the
number of induction cycles will translate in a better long-term
outcome. Standard induction therapy consists of 4 to amaximum
of six3 cycles of treatment including a proteasome inhibitor, an
immunomodulatory drug and dexamethasone. The paradigm
that improvement in response that in general is observed with
increasing number of induction cycles will lead to a better
outcome might be false. To the best of our knowledge, data from
randomized clinical trials are lacking. Therefore, we here describe
the outcome of a cohort study in which cohorts were treated with
either 4 or 8 induction cycles of KTd.
Widely accepted regimens are combinations of bortezomib,
thalidomide and dexamethasone (VTd) or bortezomib, lenali-
domide, and dexamethasone (VRd). Unfortunately, the combi-
nation of bortezomib and these Imids is associated with the
occurrence of polyneuropathy (PNP), which may require dose
reductions or early discontinuation of treatment.4 Carfilzomib is
a selective proteasome inhibitor that has irreversible binding to
the 20S proteasome resulting in accumulation of the proteasome
substrates. Previous trials showed that the incidence of PNP in
patients treated with carfilzomib is lower than with bortezomib,
which makes carfilzomib a good alternative for use in NDMM.5,6
In this single-arm, open-label, phase 2 dose escalation trial of
the European Myeloma Network the combination of carfilzomib
with thalidomide and dexamethasone (KTd) for induction and
consolidation therapy was investigated in transplant eligible
patients with NDMM. The results of 4 dose levels of carfilzomib
(27, 36, 45, 56mg/m2) have recently been published.6 Overall
response rate (ORR) after induction therapy was 93% with a
complete remission (CR) rate of 18%. ORR increased to 94%
after consolidation therapy with a CR rate of 63%. Median PFS
was 58 months and median OS was 83 months.6 There were
no significant differences in outcome between the dose levels of
carfilzomib.
We here present the results of intensified induction with 8
cycles of KTd, and compared these data to the data we obtained
from treatment with 4 cycles of KTd whereby carfilzomib was
dosed twice weekly at 56mg/m2.
This is an open-label, phase 2 trial in which 20 patients dosed
with 4 KTd induction cycles in the previous dose-escalation trial
were compared with a new cohort of patients treated with 8
induction cycles.6 Transplant eligible patients aged between 18
and 65 years with NDMM were included. Patients were treated
with 4 or 8 cycles of KTd for induction, respectively. The dose of
carfilzomib was 20mg/m2 i.v. on days 1and 2 followed by 56mg/
m2 on days 8, 9, 15, and 16 of cycle 1 and on days 1, 2, 8, 9, 15,
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and 16 of cycles 2 to 4 or 2 to 8. Thalidomide dose was 200mg
orally on days 1 through 28 and dexamethasone dose was 40mg
orally on days 1, 8, 15, and 22 of a 28-day cycle. Induction
therapy was followed by stem cell harvest after cyclophosphamide
priming (2mg/m2) and daily 10mg/kg granulocyte colony-
stimulating factor. Hereafter, patients received HDM (200mg/m2)
and ASCT followed by 4 consolidation cycles with KTd in the same
schedule as during induction therapy except a lower dose of
thalidomide (50mg). The primary endpoint was response after
induction therapy, specifically CR and very good partial response
(VGPR). Secondary endpoints were efficacy and safety, PFS andOS.
For this prospective analysis, 46 eligible patients were
analyzed, 26 patients were treated with 8 cycles of KTd induction
therapy vs 20 patients treated with 4 cycles of KTd at carfilzomib
56mg/m2. Median age was 57 years [range 37–66 years]. ISS
stages I/II/III/unknown were 43%/35%/20%/2%, respectively. A
total of 50% of patients were classified as high risk based on
cytogenetics and ISS stage; 33% of patients were classified as
standard risk. In 17% of patients, risk status was unknown,
mainly due to missing cytogenetics. Patients were considered to
be high-risk if they had t(4;14) and/or del(17p) and/or add(1q)
and/or ISS stage III.
Median follow-up was 51.4 months [range 33.3–74.1
months]. Response with 8 KTd and with 4 KTd after induction
was ≥ CR in 27% vs 20%, ≥ VGPR in 92% vs 80% and ≥ PR in
96% vs 90%. Response with 8 KTd vs 4 KTd after HDMwas CR
in 35% vs 30%. After consolidation treatment CR rate increased
to 58% vs 65%, respectively.
In patients treated with 8 KTd induction, PFS and OS at
48 months were 67% and 77% respectively, as compared with
55% and 85% after 4 KTd (Fig. 1).
Induction treatment with 8 KTd resulted in a higher incidence
of premature discontinuation of carfilzomib (12%) and dexa-
methasone (12%) than with 4 KTd (5% and 5%, respectively)
(Table 1). Reason for premature discontinuation were PNP (n=
3), anemia and fatigue (n=1), skin toxicity (n=1), progression of
disease (n=1). With 4 and 8 KTD median relative dose intensity
of carfilzomib was 98% [IQR 92–100]. Seven patients (27%)
completed 8 induction cycles without any reduction in dose level.
Grade 3 and 4 toxicity rates were higher with 8 KTd with
respect to anemia, respiratory complications, polyneuropathy,
and cardiac disorders. Cardiac events grade 3 and 4 in patients
treated with 8 KTd occurred in 4 patients (15%, heart failure
[2 patients] and hypertension [2 patients]). With 4 KTd heart
failure grade 3 was reported in 1 patient (5%).
In conclusion, in this prospective, multicenter, non-random-
ized phase 2 trial, 8 cycles of KTd resulted in slightly higher
percentages of CR and VGPR as compared to 4 KTd, with almost
all patients achieving at least a PR. However, more cardiac events
and premature discontinuation of treatment were observed.
Moreover, response percentages after HDM/ASCT as well as
after consolidation were comparable between the 2 groups and
Figure 1. A: Progression free survival, B: Overall survival.
Table 1
Adherence to Treatment Protocol During Induction and Consolidation Between Dose Levels.
Column 1
Induction 4 Induction
Cycles at 56 mg/m2
8 Induction
Cycles at 56 mg/m2
Consolidation 4 Induction
Cycles at 56 mg/m2
8 Induction
Cycles at 56 mg/m2
Patients, n 20 26 19 22
Carfilzomib
Normal completion 15 (75) 10 (38) 10 (53) 10 (45)
Dose delay, reduction and/or interruption 4 (20) 13 (50) 4 (21) 6 (27)
Premature stop 1 (5) 3 (12) 5 (26) 6 (27)
Thalidomide
Normal completion 7 (35) 7 (27) 7 (37) 9 (41)
Dose delay, reduction and/or interruption 10 (50) 16 (62) 3 (16) 3 (14)
Premature stop 3 (15) 3 (12) 9 (47) 10 (45)
Dexamethasone
Normal completion 14 (70) 13 (50) 11 (58) 10 (45)
Dose delay, reduction and/or interruption 5 (25) 10 (38) 3 (16) 5 (23)
Premature stop 1 (5) 3 (12) 5 (26) 7 (32)
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more importantly, also PFS and OS were not different. A
limitation of our study is that we used cohorts of patients instead
of a randomization. Moreover, we choose a regimen that is less
feasible with only 38% of patients being treated as planned. As a
consequence, the improvement in response was limited. There-
fore, we cannot define whether increasing response with
additional cycles of therapy will translate in a better (progression
free) survival or indicates more refractory disease with inferior
outcome.
Our data do not support lengthening induction therapy with
KTd, as the increase in response is limited and does not translate
in an improvement in PFS and OS. Moreover, feasibility was
modest with only 38% of patients receiving full dose in time.
Therefore we conclude that in transplant-eligible NDMM 4
induction cycles should remain the standard.
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